Metastatic Castration-Resistant Prostate Cancer Market to Register Stupendous Growth During the Study Period (2020–2034) Owing to the Active Participation of Pharma Companies | DelveInsight
The mCRPC market is expected to witness significant growth during the forecast period. Extensive market penetration of approved therapies in mCRPC due to label expansions and entry of new emerging therapies will be crucial factors facilitating the market growth.
New York, USA, Feb. 17, 2025 (GLOBE NEWSWIRE) — Metastatic Castration-Resistant Prostate Cancer Market to Register Stupendous Growth During the Study Period (2020–2034) Owing to the Active Participation of Pharma Companies | DelveInsight
The mCRPC market is expected to witness significant growth during the forecast period. Extensive market penetration of approved therapies in mCRPC due to label expansions and entry of new emerging therapies will be crucial factors facilitating the market growth.
DelveInsight’s Metastatic Castration-Resistant Prostate Cancer Market Insights report includes a comprehensive understanding of current treatment practices, emerging mCRPC drugs, market share of individual therapies, and current and forecasted mCRPC market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Market Report
- According to DelveInsight’s analysis, the market size of mCRPC in the 7MM was USD 6.8 billion in 2023.
- In 2023, the United States held the highest market share for mCRPC in the 7MM, contributing to ~64%, of the total market share.
- In 2023, the 7MM had 7.2 million prevalent cases of prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2024-2034).
- Prominent companies working in the domain of mCRPC, including Janssen Research and Development, Sanofi, AstraZeneca, Merck, Pfizer, Astellas Pharma, Bayer, Novartis, Curium, Orion, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, and others, are actively working on innovative mCRPC drugs. These novel mCRPC therapies are anticipated to enter the mCRPC market in the forecast period and are expected to change the market.
- Some of the key mCRPC therapies include AKEEGA, JEVTANA, LYNPARZA, TALZENNA, XOFIGO, XTANDI, ZYTIGA, PLUVICTO, RUBRACA, 177Lu-PSMA-I&T, Opevesostat (MK-5684; ODM-208), ERLEADA, Mevrometostat, CABOMETYX, TRUQAP, Masitinib, 177Lu-PNT2002, 177Lu-DOTA-rosopatamab, TAVT-45, Fuzuloparib, KPG-121, FPI-2265, Zenocutuzumab, BMS-986218, SX-682, PT-112, Vudalimab (XmAb-20717), OPDIVO, Pamufetinib (TAS-115), MVI-816 (pTVG-HP), Vobramitamab Duocarmazine (MGC018), ZEN-3694, Lorigerlimab, ModraDoc006/r, ARV-766, LAE201 (LAE002 + LAE001), 177Lu-rhPSMA-10.1, Tazemetostat, ONCT-534, LAVA-1207, Masofaniten, Saruparib (AZD5305), DB-1311/BNT324, KEYTRUDA, Ifinatamab Deruxtecan (DS-7300a, I-DXd), BMS-986365 (CC-94676), FG-3246 (FOR46), ORIC-944, and others.
- In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx® and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
- In September 2024, Oncternal Therapeutics announced its decision to discontinue its clinical trials evaluating ONCT-534, its dual-action androgen receptor inhibitor for the treatment of patients with mCRPC.
- In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).
- In April 2024, Astellas Pharma received European approval for XTANDI™ in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).
Discover which therapies are expected to grab the mCRPC market share @ Metastatic Castration-Resistant Prostate Cancer Market Report
Metastatic Castration-Resistant Prostate Cancer Overview
Metastatic castration-resistant prostate cancer (mCRPC) is an advanced form of prostate cancer where the disease has spread beyond the prostate gland and no longer responds to conventional hormone therapy (androgen deprivation therapy or ADT). It typically develops in men whose prostate cancer has been treated initially with ADT, which reduces the levels of testosterone, a hormone that fuels cancer growth. Over time, however, the cancer becomes resistant to this treatment, continuing to grow despite low testosterone levels.
The causes of mCRPC are largely linked to the mutations or adaptations in prostate cancer cells that allow them to bypass the effects of androgen deprivation. These cells may acquire the ability to produce their own androgens or activate androgen receptors in the absence of testosterone. Other genetic mutations may also contribute to the development of resistance.
Symptoms of mCRPC can vary but commonly include worsening bone pain (often in the lower back or hips), fatigue, unexplained weight loss, difficulty urinating, and signs of metastasis, such as swollen lymph nodes or breathing difficulties if the cancer spreads to the lungs. Additionally, patients may experience issues related to hormone imbalances, such as reduced sexual function or mood changes.
Diagnosis of mCRPC typically involves a combination of clinical evaluations, imaging tests (such as bone scans or CT/MRI scans), and laboratory tests. Prostate-specific antigen (PSA) levels may remain elevated even in castration-resistant cases, providing a clue to the persistence of cancer. Biopsies and genetic testing can further confirm the diagnosis and help in determining the most appropriate treatment options, including newer therapies such as immune checkpoint inhibitors or targeted therapies that address specific mutations.
Metastatic Castration-Resistant Prostate Cancer Epidemiology Segmentation
The mCRPC epidemiology section provides insights into the historical and current mCRPC patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The mCRPC market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
- Total Prevalent cases of Prostate cancer
- Five–year Prevalent cases of Prostate cancer
- Age-specific cases of Prostate cancer
- Total cases of Prostate cancer by clinical stages
- Total Prevalent cases of mCRPC
Download the report to understand which factors are driving mCRPC epidemiology trends @ Metastatic Castration-Resistant Prostate Cancer Epidemiological Insights
Metastatic Castration-Resistant Prostate Cancer Treatment Market
Despite the availability of currently approved therapies, mCRPC remains a terminal condition with an aggressive progression. Androgen deprivation therapy (ADT) is a mainstay treatment for the initial stages of metastatic disease, but unfortunately, most patients will eventually develop mCRPC and require additional systemic treatments. Managing this disease state can be particularly challenging.
Docetaxel was the only treatment option for mCRPC until 2010, demonstrating an improvement in overall survival compared to standard care. It was approved in 2004 in combination with prednisone for mCRPC. However, for many years, there were no standard second-line treatments available following failure of first-line docetaxel. In recent years, several new therapies such as JEVTANA, ZYTIGA, XTANDI, LYNPARZA, TALZENNA, AKEEGA, and others have received regulatory approval in the United States for mCRPC.
PARP inhibitors have made significant progress in this area, with AKEEGA (Janssen), followed by TALZENNA (Pfizer/Astellas Pharma) and LYNPARZA in combination (AstraZeneca/Merck), receiving approval for mCRPC in 2023. AKEEGA by Janssen is a groundbreaking advancement as the first and only dual-action tablet combining a PARP inhibitor, niraparib, with abiraterone acetate and prednisone.
Additionally, the approval of PLUVICTO has been a significant step forward in treating progressive mCRPC, offering improved survival outcomes for patients with limited treatment options. The drug has seen strong initial market performance, surpassing expectations in terms of its uptake in the US.
Learn more about the market of mCRPC @ Metastatic Castration-Resistant Prostate Cancer Treatment
Metastatic Castration-Resistant Prostate Cancer Emerging Drugs and Companies
The mCRPC pipeline possesses some drugs in mid and late-stage developments to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Anti-B7-H3 ADC (MGC018, DS-7300), PROTAC protein degrader (ARV-766), First-in-Class NTD AR Inhibitor (EPI-7386), radionuclide therapy and PSMA-Targeted therapy (177Lu-DOTA-rosopatamab, 177Lu-PNT2002), AKT inhibitor (capivasertib), CYP11A1 inhibitor (opevesostat), pyrophosphate conjugate (PT-112), and others in different lines of treatment.
Opevesostat is an oral, non-steroidal, selective CYP11A1 inhibitor developed by Orion, currently being studied for hormone-dependent cancers like prostate cancer. In July 2024, Merck and Orion announced a collaboration, granting Merck global exclusive rights to operate opevesostat for treating metastatic castration-resistant prostate cancer (mCRPC).
Merck and Orion have launched two pivotal Phase III trials, OMAHA1 (NCT06136624) and OMAHA2a (NCT06136650), to evaluate opevesostat in combination with hormone replacement therapy (HRT) for certain mCRPC patients. The final results of OMAHA1 are expected by 2028, while OMAHA2a results are anticipated by 2030. Additionally, Merck presented updated Phase II CYPIDES trial results for opevesostat in mCRPC at the ESMO Congress 2024.
Capivasertib is a new pyrrolopyrimidine-based compound that functions as an orally administered inhibitor of the serine/threonine-protein kinase AKT (protein kinase B), showing potential for anticancer effects. The company has completed the Phase Ib and Phase I/II trials of capivasertib for prostate cancer treatment. Additionally, AstraZeneca is exploring capivasertib in combination with ZYTIGA in the Phase III CAPItello-281 study for mHSPC treatment. It is also being investigated in combination with docetaxel in the Phase III CAPItello-280 study for mCRPC treatment. According to the AstraZeneca H1 2024 clinical trial appendix report published in July 2024, the company expects results from the Phase III CAPItello-280 study for mCRPC to be available in 2025 or later.
The other pipeline therapies for mCRPC include
- ERLEADA (apalutamide): Johnson & Johnson (Janssen Pharmaceutical)
- 177Lu-PSMA-I&T: Curium
- Mevrometostat (PF-06821497): Pfizer
- CABOMETYX (cabozantinib, XL184): Exelixis and Ipsen Pharma
- Masitinib: AB Science
- TAVT-45 (abiraterone acetate): Tavanta Therapeutics
- Fuzuloparib: Jiangsu Hengrui Pharmaceuticals
- KPG-121: Kangpu Biopharmaceuticals
- FPI-2265: AstraZeneca/Fusion Pharma
- BMS-986218: Bristol Myers Squibb (BMS)
- SX-682: Syntrix Pharmaceuticals
- Vudalimab (XmAb-20717): Xencor
- OPDIVO (nivolumab): Bristol Myers Squibb
- Pamufetinib (TAS-115): Taiho Pharmaceutical
- MVI-816 (pTVG-HP): Madison Vaccines
- ZEN-3694: Zenith Epigenetics
- Zenocutuzumab: Merus
- Lorigerlimab: MacroGenics
- ModraDoc006/r: Modra Pharmaceuticals
- LAE201 (LAE002 + LAE001): Laekna Therapeutics
The anticipated launch of these emerging therapies are poised to transform the mCRPC market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the mCRPC market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about mCRPC clinical trials, visit @ Metastatic Castration-Resistant Prostate Cancer Treatment Drugs
Metastatic Castration-Resistant Prostate Cancer Market Dynamics
The mCRPC market dynamics are anticipated to change in the coming years. Amgen and Xencor are currently evaluating xaluritamig (AMG 509), a STEAP1 x CD3 XmAb 2+1 bispecific antibody, in a Phase I study for patients with mCRPC, as STEAP1 is highly expressed in prostate cancers, making it an attractive target for treatment. The emergence of PASMA-PET imaging has significantly improved the diagnostic landscape of advanced prostate cancer, while the rise of bi-specifics, DAARTs, PROTAC degraders, Aniten, and ADCs is positioning mCRPC as a lucrative market in the future. To date, clinical development has mainly focused on conjugating PSMA-targeted drugs to beta-emitting radioisotopes, but alpha emitters could offer greater efficacy if the challenge of increased toxicity can be addressed.
Furthermore, many potential therapies are being investigated for the treatment of mCRPC, and it is safe to predict that the treatment space will significantly impact the mCRPC market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the mCRPC market in the 7MM.
However, several factors may impede the growth of the mCRPC market. Recent studies have been discouraging for Merck’s KEYTRUDA and Bristol-Myers Squibb’s OPDIVO, as they struggle to gain traction for their checkpoint inhibitors in prostate cancer, with limited PFS benefits from emerging therapies in heavily pretreated patients. The expected entry of XTANDI’s generic by 2026 in Europe and Japan, and 2027 in the US, is likely to erode the sales of approved drugs. Despite a variety of treatments available for mCRPC, resistance to current therapeutic agents is inevitable, with complex mechanisms of drug resistance making mCRPC treatment particularly challenging.
Moreover, mCRPC treatment poses a significant economic burden and disrupts patients’ overall well-being and QOL. Furthermore, the mCRPC market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the mCRPC market growth.
| Metastatic Castration-Resistant Prostate Cancer Report Metrics | Details |
| Study Period | 2020–2034 |
| Metastatic Castration-Resistant Prostate Cancer Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Metastatic Castration-Resistant Prostate Cancer Market Size in 2023 | USD 6.8 Billion |
| Key Metastatic Castration-Resistant Prostate Cancer Companies | Janssen Research and Development, Sanofi, AstraZeneca, Merck, Pfizer, Astellas Pharma, Bayer, Novartis, Curium, Orion, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, and others |
| Key Metastatic Castration-Resistant Prostate Cancer Therapies | AKEEGA, JEVTANA, LYNPARZA, TALZENNA, XOFIGO, XTANDI, ZYTIGA, PLUVICTO, RUBRACA, 177Lu-PSMA-I&T, Opevesostat (MK-5684; ODM-208), ERLEADA, Mevrometostat, CABOMETYX, TRUQAP, Masitinib, 177Lu-PNT2002, 177Lu-DOTA-rosopatamab, TAVT-45, Fuzuloparib, KPG-121, FPI-2265, Zenocutuzumab, BMS-986218, SX-682, PT-112, Vudalimab (XmAb-20717), OPDIVO, Pamufetinib (TAS-115), MVI-816 (pTVG-HP), Vobramitamab Duocarmazine (MGC018), ZEN-3694, Lorigerlimab, ModraDoc006/r, ARV-766, LAE201 (LAE002 + LAE001), 177Lu-rhPSMA-10.1, Tazemetostat, ONCT-534, LAVA-1207, Masofaniten, Saruparib (AZD5305), DB-1311/BNT324, KEYTRUDA, Ifinatamab Deruxtecan (DS-7300a, I-DXd), BMS-986365 (CC-94676), FG-3246 (FOR46), ORIC-944, and others |
Scope of the Metastatic Castration-Resistant Prostate Cancer Market Report
- Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment: Metastatic Castration-Resistant Prostate Cancer current marketed and emerging therapies
- Metastatic Castration-Resistant Prostate Cancer Market Dynamics: Conjoint Analysis of Emerging Metastatic Castration-Resistant Prostate Cancer Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Metastatic Castration-Resistant Prostate Cancer Market Access and Reimbursement
Discover more about mCRPC drugs in development @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials
Table of Contents
| 1 | Key Insights |
| 2 | Report Introduction |
| 3 | Executive Summary of mCRPC |
| 4 | Key Events |
| 5 | Epidemiology and Market Forecast Methodology |
| 6 | mCRPC Market Overview at a Glance |
| 6.1 | Market Share (%) Distribution of mCRPC by Class in 2020 in the 7MM |
| 6.2 | Market Share (%) Distribution of mCRPC by Class in 2034 in the 7MM |
| 7 | Disease Background and Overview |
| 7.1 | Signs and Symptoms of Prostate Cancer |
| 7.2 | Risk Factors and Causes of Prostate Cancer |
| 7.3 | Stages of Prostate Cancer |
| 7.4 | Pathophysiology of Prostate Cancer |
| 7.5 | Diagnosis of Prostate Cancer |
| 7.5.1 | Tests to Diagnose Prostate Cancer |
| 8 | Treatment and Management |
| 8.1 | Treatment Guidelines |
| 8.1.1 | National Comprehensive Cancer Network Guidelines for Prostate Cancer (2024) |
| 8.1.2 | European Society for Medical Oncology Treatment Recommendations for Prostate Cancer (2023) |
| 8.1.3 | Advanced Prostate Cancer: American Urology Association/Society of Urologic Oncology Guideline (2023) |
| 8.1.4 | European Association of Urology Guidelines for Prostate Cancer (2024) |
| 8.1.5 | Pan-Asian Adapted ESMO Clinical Practice Guidelines for the Diagnosis and Treatment (2022) |
| 8.1.6 | Japanese Urological Association: 2016 |
| 8.1.7 | Japanese Clinical Practice Guidelines for Prostate Cancer (2023) |
| 8.1.8 | Advanced Prostate Cancer Consensus Conference (APCCC): 2021 |
| 8.1.9 | NICE Guidelines for the Treatment of Advanced Prostate Cancer, 2021 |
| 8.1.10 | Cancer Committee of the French Association of Urology Guidelines, 2020 |
| 9 | Epidemiology and Patient Population |
| 9.1 | Key Findings |
| 9.2 | Assumptions and Rationale |
| 9.3 | Total Prevalent Cases of Prostate Cancer in the 7MM |
| 9.4 | Five-year Prevalent Cases of Prostate Cancer in the 7MM |
| 9.5 | Total Prevalent Cases of mCRPC in the 7MM |
| 9.6 | The United States |
| 9.6.1 | Five-year Prevalent Cases of Prostate Cancer in the US |
| 9.6.2 | Age-specific Cases of Prostate Cancer in the US |
| 9.6.3 | Total Cases of Prostate Cancer by Clinical Stages in the US |
| 9.6.4 | Total Prevalent Cases of mCRPC in the US |
| 9.7 | EU4 and the UK |
| 9.7.1 | Five-year Prevalent Cases of Prostate Cancer in EU4 and the UK |
| 9.7.2 | Age-specific Cases of Prostate Cancer in the EU4 and the UK |
| 9.7.3 | Total Cases of Prostate Cancer by Clinical Stages in the EU4 and the UK |
| 9.7.4 | Total Prevalent Cases of mCRPC in EU4 and the UK |
| 9.8 | Japan |
| 9.8.1 | Five-year Prevalent Cases of Prostate Cancer in Japan |
| 9.8.2 | Age-specific Cases of Prostate Cancer in Japan |
| 9.8.3 | Total Cases of Prostate Cancer by Clinical Stages in Japan |
| 9.8.4 | Total Prevalent Cases of mCRPC in Japan |
| 10 | Patient Journey |
| 11 | Marketed drug |
| 11.1 | Key Competitors |
| 11.2 | JEVTANA (cabazitaxel): Sanofi |
| 11.2.1 | Product Description |
| 11.2.2 | Regulatory Milestones |
| 11.2.3 | Other Developmental Activities |
| 11.2.4 | Safety and Efficacy |
| 11.3 | XOFIGO (radium-223 dichloride): Bayer |
| 11.3.1 | Product Description |
| 11.3.2 | Regulatory Milestones |
| 11.3.3 | Other Developmental Activities |
| 11.3.4 | Clinical Development |
| 11.3.5 | Safety and Efficacy |
| 11.4 | ZYTIGA (abiraterone acetate): Johnson & Johnson (Janssen Biotech) |
| 11.4.1 | Product Description |
| 11.4.2 | Regulatory Milestones |
| 11.4.3 | Other Developmental Activities |
| 11.4.4 | Safety and Efficacy |
| 11.5 | XTANDI (enzalutamide): Astellas Pharma/Pfizer |
| 11.5.1 | Product Description |
| 11.5.2 | Regulatory Milestones |
| 11.5.3 | Other Developmental Activities |
| 11.5.4 | Clinical Development activity |
| 11.5.5 | Safety and Efficacy |
| 11.6 | RUBRACA (rucaparib): Pharma& Schwiez (Pharmaand GmbH) |
| 11.6.1 | Product Description |
| 11.6.2 | Regulatory Milestones |
| 11.6.3 | Other Development Activities |
| 11.6.4 | Clinical Development |
| 11.6.5 | Safety and Efficacy |
| 11.7 | PLUVICTO (177Lu-PSMA-617): Novartis Pharmaceuticals |
| 11.7.1 | Product Description |
| 11.7.2 | Regulatory Milestones |
| 11.7.3 | Other Development Activities |
| 11.7.4 | Clinical Development |
| 11.7.5 | Safety and Efficacy |
| 11.8 | AKEEGA (niraparib and abiraterone acetate): Johnson & Johnson (Janssen Pharmaceuticals) |
| 11.8.1 | Product Description |
| 11.8.2 | Regulatory Milestones |
| 11.8.3 | Other Developmental Activities |
| 11.8.4 | Clinical Development |
| 11.8.5 | Safety and Efficacy |
| 11.9 | LYNPARZA (olaparib): AstraZeneca/Merck Sharp & Dohme |
| 11.9.1 | Product Description |
| 11.9.2 | Regulatory Milestones |
| 11.9.3 | Other Developmental Activities |
| 11.9.4 | Clinical Development |
| 11.9.5 | Safety and Efficacy |
| 11.1 | TALZENNA (talazoparib): Pfizer |
| 11.10.1 | Product Description |
| 11.10.2 | Regulatory Milestones |
| 11.10.3 | Other Developmental Activities |
| 11.10.4 | Clinical Development |
| 11.10.5 | Safety and Efficacy |
| 12 | Emerging Drugs |
| 12.1 | Key Competitors |
| 12.2 | Safety and Efficacy Data of Phase I/II Emerging Drugs |
| 12.3 | Safety and Efficacy Data of Phase I Emerging Drugs |
| 12.4 | ERLEADA (apalutamide): Johnson & Johnson (Janssen Pharmaceutical) |
| 12.4.1 | Product Description |
| 12.4.2 | Other Developmental Activities |
| 12.4.3 | Clinical Development |
| 12.4.4 | Safety and Efficacy |
| 12.5 | 177Lu-PSMA-I&T: Curium |
| 12.5.1 | Product Description |
| 12.5.2 | Other Developmental Activities |
| 12.5.3 | Clinical Development |
| 12.5.4 | Safety and Efficacy |
| 12.6 | Opevesostat (MK-5684; ODM-208): Merck and Orion |
| 12.6.1 | Product Description |
| 12.6.2 | Other Developmental Activities |
| 12.6.3 | Clinical Development |
| 12.6.4 | Safety and Efficacy |
| 12.7 | Mevrometostat (PF-06821497): Pfizer |
| 12.7.1 | Product Description |
| 12.7.2 | Other Developmental Activities |
| 12.7.3 | Clinical Development |
| 12.7.4 | Safety and Efficacy |
| 12.8 | CABOMETYX (cabozantinib, XL184): Exelixis and Ipsen Pharma |
| 12.8.1 | Product Description |
| 12.8.2 | Other Developmental Activities |
| 12.8.3 | Clinical Development |
| 12.8.4 | Safety and Efficacy |
| 12.9 | TRUQAP (capivasertib, AZD5363): AstraZeneca |
| 12.9.1 | Product Description |
| 12.9.2 | Other Developmental Activities |
| 12.9.3 | Clinical Development |
| 12.9.4 | Safety and Efficacy |
| 12.1 | Masitinib: AB Science |
| 12.10.1 | Product Description |
| 12.10.2 | Other Developmental Activities |
| 12.10.3 | Clinical Development |
| 12.10.4 | Safety and Efficacy |
| 12.11 | 177Lu-PNT2002: Lantheus and Eli Lilly/POINT Biopharma |
| 12.11.1 | Product Description |
| 12.11.2 | Other Developmental Activities |
| 12.11.3 | Clinical Development |
| 12.11.4 | Safety and Efficacy |
| 12.12 | 177Lu-DOTA-rosopatamab (TLX591): Telix Pharmaceuticals |
| 12.12.1 | Product Description |
| 12.12.2 | Other Developmental Activities |
| 12.12.3 | Clinical Development |
| 12.12.4 | Safety and Efficacy |
| 12.13 | TAVT-45 (abiraterone acetate): Tavanta Therapeutics |
| 12.13.1 | Product Description |
| 12.13.2 | Other Developmental Activities |
| 12.13.3 | Clinical Development |
| 12.13.4 | Safety and Efficacy |
| 12.14 | Fuzuloparib: Jiangsu Hengrui Pharmaceuticals |
| 12.14.1 | Product Description |
| 12.14.2 | Other Developmental Activities |
| 12.14.3 | Clinical Development |
| 12.15 | KPG-121: Kangpu Biopharmaceuticals |
| 12.15.1 | Product Description |
| 12.15.2 | Other Developmental Activities |
| 12.15.3 | Clinical Development |
| 12.15.4 | Safety and Efficacy |
| 12.16 | FPI-2265: AstraZeneca/Fusion Pharma |
| 12.16.1 | Product Description |
| 12.16.2 | Other Developmental Activities |
| 12.16.3 | Clinical Development |
| 12.16.4 | Safety and Efficacy |
| 12.17 | BMS-986218: Bristol Myers Squibb (BMS) |
| 12.17.1 | Product Description |
| 12.17.2 | Clinical Development |
| 12.18 | SX-682: Syntrix Pharmaceuticals |
| 12.18.1 | Product Description |
| 12.18.2 | Clinical Development |
| 12.18.3 | Safety and Efficacy |
| 12.19 | PT-112: Promontory Therapeutics |
| 12.19.1 | Product Description |
| 12.19.2 | Other Developmental Activities |
| 12.19.3 | Clinical Development |
| 12.19.4 | Safety and Efficacy |
| 12.2 | Vudalimab (XmAb-20717): Xencor |
| 12.20.1 | Product Description |
| 12.20.2 | Other Developmental Activities |
| 12.20.3 | Clinical Development |
| 12.20.4 | Safety and Efficacy |
| 12.21 | OPDIVO (nivolumab): Bristol Myers Squibb |
| 12.21.1 | Product Description |
| 12.21.2 | Other Developmental Activities |
| 12.21.3 | Clinical Development |
| 12.21.4 | Safety and Efficacy |
| 12.22 | Pamufetinib (TAS-115): Taiho Pharmaceutical |
| 12.22.1 | Product Description |
| 12.22.2 | Clinical Development |
| 12.22.3 | Safety and Efficacy |
| 12.23 | MVI-816 (pTVG-HP): Madison Vaccines |
| 12.23.1 | Product Description |
| 12.23.2 | Other Developmental Activity |
| 12.23.3 | Clinical Development |
| 12.23.4 | Safety and Efficacy |
| 12.24 | Vobramitamab Duocarmazine (MGC018): MacroGenics |
| 12.24.1 | Product Description |
| 12.24.2 | Other Developmental Activities |
| 12.24.3 | Clinical Development |
| 12.24.4 | Safety and Efficacy |
| 12.25 | ZEN-3694: Zenith Epigenetics |
| 12.25.1 | Product Description |
| 12.25.2 | Other Developmental Activities |
| 12.25.3 | Clinical Development |
| 12.25.4 | Safety and Efficacy |
| 12.26 | Zenocutuzumab: Merus |
| 12.26.1 | Product Description |
| 12.26.2 | Clinical Development |
| 12.27 | Lorigerlimab: MacroGenics |
| 12.27.1 | Product Description |
| 12.27.2 | Other Developmental Activities |
| 12.27.3 | Clinical Development |
| 12.27.4 | Safety and Efficacy |
| 12.28 | ModraDoc006/r: Modra Pharmaceuticals |
| 12.28.1 | Product Description |
| 12.28.2 | Other Developmental Activities |
| 12.28.3 | Clinical Development |
| 12.28.4 | Safety and Efficacy |
| 12.29 | ARV-766: Arvinas and Novartis |
| 12.29.1 | Product Description |
| 12.29.2 | Other Developmental Activities |
| 12.29.3 | Clinical Development |
| 12.29.4 | Safety and Efficacy |
| 12.3 | LAE201 (LAE002 + LAE001): Laekna Therapeutics |
| 12.30.1 | Product Description |
| 12.30.2 | Other Developmental Activities |
| 12.30.3 | Clinical Development |
| 12.30.4 | Safety and Efficacy |
| 13 | mCRPC: 7MM Analysis |
| 13.1 | Key Findings |
| 13.2 | Market Outlook |
| 13.3 | Conjoint Analysis |
| 13.4 | Key Market Forecast Assumptions |
| 13.4.1 | Cost Assumptions and Rebates |
| 13.4.2 | Pricing Trends |
| 13.4.3 | Analogue Assessment |
| 13.4.4 | Launch Year and Therapy Uptake |
| 13.5 | Total Market Size of mCRPC in the 7MM |
| 13.6 | Total Market Size of mCRPC by Class in the 7MM |
| 13.7 | United States Market Size |
| 13.7.1 | Total Market Size of mCRPC in the United States |
| 13.7.2 | Market Size of mCRPC by Therapies in the United States |
| 13.8 | EU4 and the UK Market Size |
| 13.8.1 | Total Market Size of mCRPC in EU4 and the UK |
| 13.8.2 | Market Size of mCRPC by Therapies in EU4 and the UK |
| 13.9 | Japan |
| 13.9.1 | Total Market size of mCRPC in Japan |
| 13.9.2 | Market Size of mCRPC by Therapies in Japan |
| 14 | Unmet Needs |
| 15 | SWOT Analysis |
| 16 | KOL Views |
| 17 | Market Access and Reimbursement |
| 17.1 | United States |
| 17.1.1 | Centre for Medicare & Medicaid Services (CMS) |
| 17.2 | EU4 and the UK |
| 17.2.1 | Germany |
| 17.2.2 | France |
| 17.2.3 | Italy |
| 17.2.4 | Spain |
| 17.2.5 | United Kingdom |
| 17.3 | Japan |
| 17.3.1 | MHLW |
| 17.4 | Prostate Cancer Market Access and Reimbursement |
| 18 | Appendix |
| 18.1 | Bibliography |
| 18.2 | Report Methodology |
| 19 | DelveInsight Capabilities |
| 20 | Disclaimer |
| 21 | About DelveInsight |
Related Reports
Metastatic Castration-Resistant Prostate Cancer Pipeline
Metastatic Castration-Resistant Prostate Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key mCRPC companies, including Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma, Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc., Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, among others.
Prostate Cancer Market
Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others.
Prostate Cancer Pipeline
Prostate Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key prostate cancer companies, including Curium, Merck, Telix Pharmaceuticals, Exelixis, AstraZeneca, AB Science, Lantheus, Pfizer, Jiangsu Hengrui Pharmaceuticals, Modra Pharmaceuticals, Bristol-Myers Squibb, MacroGenics, Syntrix Pharmaceuticals, Zenith Epigenetics, Xencor, Bristol Myers Squibb, Merus, Phosplatin Therapeutics, Laekna Therapeutics, Tavanta Therapeutics, Madison Vaccines, Taiho Pharmaceutical, Kangpu Biopharmaceuticals, Arvinas, Candel Therapeutics, Blue Earth Therapeutics, Ipsen Biopharmaceuticals, LAVA Therapeutics, Essa Pharma, Poseida Therapeutics, Janux Therapeutics, Aurigene Oncology, Sathgen Therapeutics, Full-Life Technologies, NextPoint Therapeutics, AbbVie, SL VAXiGEN, Sorrento Therapeutics, Inc., 858 Therapeutics, Avacta Life Sciences Ltd, Nammi Therapeutics, BeiGene, DualityBio, among others.
Metastatic Prostate Cancer Market
Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others.
Metastatic Castration-Sensitive Prostate Cancer Market
Metastatic Castration-Sensitive Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCSPC companies including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, among others.
Oncology Conference Coverage Services
DelveInsight’s Oncology Conference Coverage Services offer a thorough analysis of outcomes from major events like ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, the European CAR T-cell Meeting, and IASLC. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies.
Get in touch with us today to learn how we can provide AACR coverage exclusively for you at the AACR Meeting 2025
Other Business Consulting Services
Healthcare Competitive Intelligence
Healthcare Licensing Services
Healthcare Portfolio Management
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. IndiaShorts takes no editorial responsibility for the same.